Protalix Biotherapeutics Inc., of Carmiel, Israel, reported 2014 revenues of $13.7 million, compared to $10.5 million for 2013. Revenues from sales of Elelyso (taliglucerase alfa) increased 53.6 percent, to $9.1 million, compared to $5.9 million in 2013, primarily due to $3.5 million in revenues recorded from sales in Brazil under a supply and technology transfer agreement.